TY - JOUR
T1 - Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection
AU - McKibben, Rebeccah A.
AU - Margolick, Joseph B.
AU - Grinspoon, Steven
AU - Li, Xiuhong
AU - Palella, Frank J.
AU - Kingsley, Lawrence A.
AU - Witt, Mallory D.
AU - George, Richard T.
AU - Jacobson, Lisa P.
AU - Budoff, Matthew
AU - Tracy, Russell P.
AU - Brown, Todd T.
AU - Post, Wendy S.
N1 - Publisher Copyright:
© 2015 The Author. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
PY - 2015/4/15
Y1 - 2015/4/15
N2 - Background Heightened immune activation among human immunodeficiency virus (HIV)-infected persons may contribute to atherosclerosis. We assessed associations of serologic markers of monocyte activation, soluble CD163 (sCD163) and soluble CD14 (sCD14), and monocyte chemoattractant protein 1 (CCL2) with subclinical atherosclerosis among men with and those without HIV infection in the Multicenter AIDS Cohort Study. Methods. We performed noncontrast computed tomography on 906 men (566 HIV-infected men and 340 HIV-uninfected men), 709 of whom also underwent coronary computed tomographic angiography. Associations between each biomarker and the prevalence of coronary plaque, the prevalence of stenosis of ≥ 50%, and the extent of plaque were assessed by logistic and linear regression, adjusting for age, race, HIV serostatus, and cardiovascular risk factors. Results. Levels of all biomarkers were higher among HIV-infected men, of whom 81% had undetectable HIV RNA, and were associated with lower CD4 + T-cell counts. In the entire population and among HIV-infected men, higher biomarker levels were associated with a greater prevalence of coronary artery stenosis of ≥ 50%. Higher sCD163 levels were also associated with greater prevalences of coronary artery calcium, mixed plaque, and calcified plaque; higher CCL2 levels were associated with a greater extent of noncalcified plaque. Conclusions. sCD163, sCD14, and CCL2 levels were elevated in treated HIV-infected men and associated with atherosclerosis. Monocyte activation may increase the risk for cardiovascular disease in individuals with HIV infection.
AB - Background Heightened immune activation among human immunodeficiency virus (HIV)-infected persons may contribute to atherosclerosis. We assessed associations of serologic markers of monocyte activation, soluble CD163 (sCD163) and soluble CD14 (sCD14), and monocyte chemoattractant protein 1 (CCL2) with subclinical atherosclerosis among men with and those without HIV infection in the Multicenter AIDS Cohort Study. Methods. We performed noncontrast computed tomography on 906 men (566 HIV-infected men and 340 HIV-uninfected men), 709 of whom also underwent coronary computed tomographic angiography. Associations between each biomarker and the prevalence of coronary plaque, the prevalence of stenosis of ≥ 50%, and the extent of plaque were assessed by logistic and linear regression, adjusting for age, race, HIV serostatus, and cardiovascular risk factors. Results. Levels of all biomarkers were higher among HIV-infected men, of whom 81% had undetectable HIV RNA, and were associated with lower CD4 + T-cell counts. In the entire population and among HIV-infected men, higher biomarker levels were associated with a greater prevalence of coronary artery stenosis of ≥ 50%. Higher sCD163 levels were also associated with greater prevalences of coronary artery calcium, mixed plaque, and calcified plaque; higher CCL2 levels were associated with a greater extent of noncalcified plaque. Conclusions. sCD163, sCD14, and CCL2 levels were elevated in treated HIV-infected men and associated with atherosclerosis. Monocyte activation may increase the risk for cardiovascular disease in individuals with HIV infection.
KW - atherosclerosis
KW - human immunodeficiency virus
KW - inflammation
KW - monocyte activation
KW - plaque
UR - http://www.scopus.com/inward/record.url?scp=84926646827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926646827&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiu594
DO - 10.1093/infdis/jiu594
M3 - Article
C2 - 25362192
AN - SCOPUS:84926646827
SN - 0022-1899
VL - 211
SP - 1219
EP - 1228
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 8
ER -